BELOTTI, ALESSIA
BELOTTI, ALESSIA
Universita' degli Studi di MILANO
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
2021 F. Gay, P. Musto, D. Rota-Scalabrini, L. Bertamini, A. Belotti, M. Galli, M. Offidani, E. Zamagni, A. Ledda, M. Grasso, S. Ballanti, A. Spadano, M. Cea, F. Patriarca, M. D'Agostino, A. Capra, N. Giuliani, P. de Fabritiis, S. Aquino, A. Palmas, B. Gamberi, R. Zambello, M.T. Petrucci, P. Corradini, M. Cavo, M. Boccadoro
Sinonasal teratocarcinosarcoma treated with surgery and proton beam therapy: Clinical, histological aspects and differential diagnosis of a new case
2021 A. Belotti, L. Carpenito, A.M. Bulfamante, A. Maccari, G. Bulfamante
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
2021 R. Mina, A.P. Falcone, S. Bringhen, A.M. Liberati, N. Pescosta, M.T. Petrucci, G. Ciccone, A. Capra, F. Patriarca, D. Rota-Scalabrini, F. Bonello, C. Musolino, M. Cea, R. Zambello, P. Tacchetti, A. Belotti, C. Cellini, L. Paris, M. Grasso, S. Aquino, L. De Paoli, G. De Sabbata, S. Ballanti, M. Offidani, M. Boccadoro, F. Monaco, P. Corradini, A. Larocca